BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1813880)

  • 1. [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
    Błasińska-Morawiec M; Płuzańska A; Krykowski E; Robak T; Mrówka I
    Pol Arch Med Wewn; 1991 Oct; 86(4):274-80. PubMed ID: 1813880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen].
    Höffken K; Ippisch A; Pfeiffer R; Becher R; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1985 Apr; 110(16):618-23. PubMed ID: 3838719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of the results of short-term polychemotherapy by the MOPP program of Hodgkin's disease stages III and IV].
    Hansz J; Burchardt K; Komarnicki M; Trepińska E; Psuja P
    Pol Arch Med Wewn; 1984 Dec; 72(6):293-8. PubMed ID: 6549512
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
    Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
    J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
    Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
    J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
    Sampi K; Honda T; Hattori M
    Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
    [No Abstract]   [Full Text] [Related]  

  • 13. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol.
    Silingardi V; Federico M; Frassoldati A; Barbieri F; Palomba G; Mauri C
    Acta Haematol; 1989; 82(4):179-86. PubMed ID: 2511719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced Hodgkin's disease with modified MOPP regimens. A long-term observation.
    Koza I; Bohunický L; Svancárová L; Mardiak J; Gyárfás J; Cerný V
    Neoplasma; 1989; 36(6):709-18. PubMed ID: 2615874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
    Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
    J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
    Fiacchini M; Lauria F; Mazza P; Cantore M; Gherlinzoni F; Tura S
    Haematologica; 1985; 70(2):148-54. PubMed ID: 3924778
    [No Abstract]   [Full Text] [Related]  

  • 20. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.